Score Overview
Explore the 2021 public Archive ranking →
Where Supernus Pharmaceuticals Inc has ranked, year by year
Showing all available years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- SUPN
2017: 51.6% · 2021: 23.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 43.97 | — |
1 Year2025-09-29 | $ 47.60 | -7.63% |
5 Years2021-09-29 | $ 26.85 | 63.76% |
10 Years2016-09-29 | $ 24.63 | 78.52% |
All Time2012-05-01 | $ 5.37 | 8x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | All Time2012-05-01 |
|---|---|---|---|---|---|
| Price | $ 43.97 | $ 47.60 | $ 26.85 | $ 24.63 | $ 5.37 |
| Return | — | -7.63% | 63.76% | 78.52% | 8x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 830M | -$ 109M | $ 372M |
| 2025 | $ 718M | -$ 38M | $ 308M |
| 2024 | $ 661M | $ 73M | $ 453M |
| 2023 | $ 607M | $ 1M | $ 254M |
| 2022 | $ 667M | $ 60M | $ 461M |
| 2021 | $ 579M | $ 53M | $ 339M |
| 2020 | $ 520M | $ 126M | $ 422M |
| 2019 | $ 392M | $ 113M | $ 347M |
| 2018 | $ 408M | $ 110M | $ 356M |
| 2017 | $ 302M | $ 57M | $ 140M |
| 2016 | $ 215M | $ 91M | $ 90M |
| 2015 | $ 144M | $ 14M | $ 62M |
| 2014 | $ 122M | $ 19M | $ 74M |
| 2013 | $ 12M | -$ 92M | $ 82M |
| IPO2012 | $ 1M | -$ 46M | $ 88M |
Supernus Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 520M to $ 718M and net income went from $ 126M to -$ 38M. Revenue increased in 4 of those 5 years; net income in 2.
Between 2015 and 2025, revenue grew from $ 144M to $ 718M and net income went from $ 14M to -$ 38M. Revenue increased in 8 of those 10 years; net income in 5.
Supernus Pharmaceuticals Inc currently holds a 5-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.
Membership
Continue SUPN’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
Explore other companies
NanobiotixNBTX· revenue grew in 60% of years
Rani Therapeutics Holdings IncRANI· revenue grew in 60% of years
4D Molecular Therapeutics IncFDMT· revenue grew in 67% of years
Intellia Therapeutics IncNTLA· revenue grew in 60% of years
Pacific Biosciences of CaliforniaPACB· revenue grew in 40% of years
